Loomis Sayles Announces Changes to Global Fixed Income Team Leadership
10.9.2018 03:00:00 EEST | Business Wire | Press release
Loomis, Sayles & Company, an affiliate of Natixis Investment Managers, announced today that Kenneth Buntrock, portfolio manager and co-team leader of the global fixed income team, will retire in March 2019 after 21 years with the company. In preparation for Ken’s retirement, longstanding portfolio managers Lynda Schweitzer and Scott Service will assume leadership roles effective immediately, joining David Rolley as co-team leaders. The team oversees approximately $29.61 billion in institutional and retail assets for global clients.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180909005021/en/
“We are grateful to Ken for more than 20 years of service and leadership at Loomis Sayles,” said Kevin Charleston, chief executive officer. “His dedication is reflected within the success and growth of the Loomis Sayles global bond capabilities over the past two decades, and we wish him the best in retirement.”
Until his retirement date, Ken will continue in his leadership and portfolio management roles to ensure a seamless transition and provide continuity for clients.
This transition is part of a comprehensive succession plan that was initiated in 2007, when Lynda was named portfolio manager following her six-year tenure as a global portfolio specialist and trader for the team. Similarly, Scott joined the team in 2004, became portfolio manager on a variety of global credit strategies in 2011 and was named portfolio manager on all remaining global bond products in 2014.
“We believe this is the ideal time to elevate Lynda and Scott in recognition of their tenure, experience and track records as portfolio managers,” said Jae Park, chief investment officer. “Lynda and Scott have been vital members of the global fixed income team working in close partnership with Ken and David for over 15 years, and their leadership will be integral to the success of our global bond capabilities moving forward.”
David Rolley will continue his portfolio management responsibilities with Lynda and Scott for the global fixed income portfolios, as well as the emerging market fixed income team portfolios. There will be no changes to the team’s style or investment philosophy. David, Lynda and Scott will continue to report to Jae Park, chief investment officer.
BIOGRAPHICAL INFORMATION: DAVID W. ROLLEY, CFA
David Rolley
is a vice president, portfolio manager and co-team leader of the global
fixed income team and emerging market debt group at Loomis, Sayles &
Company. With 38 years of investment industry experience, David
co-manages a suite of global bond, global credit and global allocation
products. Prior to joining Loomis Sayles in 1994, he was a principal and
director of international capital market research at DRI/McGraw-Hill.
His responsibilities included international interest rate and currency
forecasting, and risk management consulting. David was also corporate
vice president and senior US economist for the institutional equity
group at Drexel Burnham Lambert, and chief financial economist at Chase
Econometrics. David earned a BA from Occidental College and studied
post-graduate economics at the University of Pennsylvania. He is a past
president of the Boston Association of Business Economists.
BIOGRAPHICAL INFORMATION: LYNDA SCHWEITZER, CFA
Lynda
Schweitzer is a vice president portfolio manager and co-team leader of
the global fixed income team at Loomis, Sayles & Company. With 32 years
of investment industry experience, she co-manages a suite of global bond
and global credit products. Lynda is also a member of the macro
strategies, developed markets sovereign and global credit sector teams.
Prior to joining Loomis Sayles in 2001 as a global portfolio specialist
and trader, she worked at Putnam Investments as a global bond trader for
both developed and emerging markets. In her tenure at Putnam, Lynda was
also a global fixed income trading assistant and custody operations
supervisor. Previously, she worked for State Street Bank and Trust Co.
as a fund accountant, responsible for custody and pricing of global
fixed income funds. Lynda earned a BA from the University of Rochester
and an MBA from Boston University.
BIOGRAPHICAL INFORMATION: SCOTT M. SERVICE, CFA
Scott
Service is a vice president, portfolio manager and co-team leader of the
global fixed income team at of Loomis, Sayles & Company. He co-manages a
suite of global bond and global credit products. Scott joined Loomis
Sayles in 1995 and was promoted to credit analyst in 1999. Between 2001
and 2003, he worked in Paris for Loomis Sayles’ parent company, Natixis
Investment Managers, covering European credits across various industries
and honing his international credit analysis skills. Scott returned to
the Loomis Sayles fixed income team in 2003 and became leader of the
global credit sector team. In 2004, he joined the global fixed income
team. Previously Scott he held financial accounting positions at both
State Street Bank and PNC Bank. He earned a BS from Babson College and
an MBA from Bentley College.
ABOUT LOOMIS SAYLES
Since 1926, Loomis, Sayles & Company has
helped fulfill the investment needs of institutional and mutual fund
clients worldwide. The firm’s performance-driven investors integrate
deep proprietary research and integrated risk analysis to make informed,
judicious decisions. Teams of portfolio managers, strategists, research
analysts and traders collaborate to assess market sectors and identify
investment opportunities wherever they may lie, within traditional asset
classes or among a range of alternative investments. Loomis Sayles has
the resources, foresight and the flexibility to look far and wide for
value in broad and narrow markets in its commitment to deliver
attractive sustainable returns for clients. This rich tradition has
earned Loomis Sayles the trust and respect of clients worldwide, for
whom it manages $264.4 billion** in assets (as of June 30, 2018).
Total strategy assets include all assets managed by the respective team.
**Includes the assets of Loomis, Sayles & Co., LP, and Loomis Sayles Trust Company, LLC. Loomis Sayles Trust Company is a wholly owned subsidiary of Loomis, Sayles & Company, LP.
ABOUT NATIXIS INVESTMENT MANAGERS
Natixis Investment
Managers serves financial professionals with more insightful ways to
construct portfolios. Powered by the expertise of 26 specialized
investment managers globally, we apply Active Thinking℠ to deliver
proactive solutions that help clients pursue better outcomes in all
markets. Natixis ranks among the world’s largest asset management firms¹
($988.4 billion / €846.5 billion AUM²).
Natixis Investment Managers includes all of the investment management and distribution entities affiliated with Natixis Distribution, L.P. and Natixis Investment Managers S.A.
¹Cerulli Quantitative Update: Global Markets 2018 ranked Natixis
Investment Managers as the 16th largest asset manager in the world based
on assets under management as of December 31, 2017.
² Net
asset value as of June 30, 2018. Assets under management (“AUM”), as
reported, may include notional assets, assets serviced, gross assets and
other types of non-regulatory AUM.
1 As of July 31, 2018.
MALR022378
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180909005021/en/
Contact information
Loomis, Sayles & Company
Orla O’Brien, +1 617-478-7480
oobrien@loomissayles.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
